Show simple item record

dc.contributor.authorPurroy Garcia, Francisco
dc.contributor.authorArque, Gloria
dc.contributor.authorMauri-Capdevila, Gerard
dc.contributor.authorGarcía-Vázquez, Cristina
dc.contributor.authorVicente-Pascual, Mikel
dc.contributor.authorPereira, Cristina
dc.contributor.authorVazquez-Justes, Daniel
dc.contributor.authorTorres-Querol, Coral
dc.contributor.authorVena Martínez, Ana Belén
dc.contributor.authorAbilleira, Sònia
dc.contributor.authorCardona, Pere
dc.contributor.authorForné Izquierdo, Carles
dc.contributor.authorJiménez-Fàbrega, Xavier
dc.contributor.authorPagola, Jorge
dc.contributor.authorPortero Otín, Manuel
dc.contributor.authorRodríguez-Campello, Ana
dc.contributor.authorRovira, Àlex
dc.contributor.authorFàbregas, Joan Martí
dc.description.abstractRationale: Remote ischemic perconditioning during cerebral ischemia (RIPerC) refers to the application of brief episodes of transient limb ischemia commonly to a limb, it represents a new safe, simple and low-cost paradigm in neuroprotection. Aim and/or Hypothesis: To evaluate the effects of RIPerC on acute ischemic stroke (AIS) patients, applied in the ambulance, to improve functional outcomes compared with standard of care. Sample Size Estimates: A sample size of 286 patients in each arm achieves 80% power to detect treatment differences of 14% in the outcome, using a two-sided binomial test at significance level of 0.05, assuming that 40% of the control patients will experience good outcome and an initial misdiagnosis rate of 29%. Methods and Design: We aim to conduct a multicentre study of pre-hospital RIPerC application in AIS patients. A total of 572 adult patients diagnosed of suspected clinical stroke within 8 h of symptom onset and clinical deficit >0 according to prehospital rapid arterial occlusion evaluation (RACE) scale score will be randomized, in blocks of size 4, to RIPerC or sham. Patients will be stratified by RACE score scale. RIPerC will be started in the ambulance before hospital admission and continued in the hospital if necessary. It will consist of five cycles of electronic tourniquet inflation and deflation (5 min each). The cuff pressure for RIPerC will be 200 mmHg during inflation. Sham will only simulate vibration of the device. Study Outcome(s): The primary outcome will be the difference in the proportion of patients with good outcomes as defined by a mRS score of 2 or less at 90 days. Secondary outcomes to be monitored will include early neurological improvement rate, treatment related serious adverse event rates, size of the infarct volume, symptomatic intracranial hemorrhage, metabolomic and lipidomic response to RIPerC and Neuropsychological evaluation at 90 days. Discussion: Neuroprotective therapies could not only increase the benefits of available reperfusion therapies among AIS patients but also provide an option for patients who are not candidates for these treatments. REMOTE-CAT will investigate the clinical benefit of RIC as a new neuroprotective strategy in AIS.ca_ES
dc.description.sponsorshipAquest treball ha estat finançat per: l'Agència de Gestió d'Ajuts Universitaris i de Recerca de la Generalitat de Catalunya 2017 SGR 1628, Instituto de Salud Carlos III, European Union (EU) PI17-01725 i INVICTUS plus Research Network (Carlos III Health Institute)ca_ES
dc.publisherFrontiers Mediaca_ES
dc.relation.isformatofReproducció del document publicat a
dc.relation.ispartofFrontiers in Neurology, 2020, vol. 11, núm. 569696, p. 1-7ca_ES
dc.rightscc-by (c) Purroy et al., 2020ca_ES
dc.subjectIschemic strokeca_ES
dc.subjectInfarct sizeca_ES
dc.titleREMOTE ischemic perconditioning among acute ischemic stroke patients in Catalonia: REMOTE-CAT PROJECTca_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

cc-by (c) Purroy et al., 2020
Except where otherwise noted, this item's license is described as cc-by (c) Purroy et al., 2020